Amifostine, cytoprotective agent (ab141060)
Key features and details
- Broad spectrum cytoprotective agent; inactive prodrug of WR-1065
- CAS Number: 20537-88-6
- Purity: > 98%
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Amifostine, cytoprotective agent -
Description
Broad spectrum cytoprotective agent; inactive prodrug of WR-1065 -
Biological description
Broad spectrum cytoprotective agent. Inactive prodrug of WR-1065. In vitro effects include p53 activation and indirect activation of proteins, including Bcl-2 and HIF-1α, involved in DNA repair and apoptosis.
-
Purity
> 98% -
CAS Number
20537-88-6 -
Chemical structure
Properties
-
Chemical name
2-[(3-Aminopropyl)amino]ethanethiol 1-(dihydrogen phosphate) -
Molecular weight
214.22 -
Molecular formula
C5H15N2O3PS -
PubChem identifier
2141 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in water to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
OP(=O)(O)SCCNCCCN -
Source
Synthetic
-
Research areas
Images
-
Functional Studies - Amifostine, cytoprotective agent (ab141060)
Saso2 cells were incubated at 37°C for 24 hours with vehicle control (0 μM) and different concentrations of Amifostine (ab141060). Decreased expression of CDK1 (phospho Y15) (ab133463) in Saso2 cells correlates with an increase in Amifostine concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab133463 at 1 μg/ml and ab32384 at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 and visualised using ECL development solution.
